Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BXRX =MC $80 M--FDA DECISION in 17 DAYS
BXRX =MC $79 M -Cash $20 M- Shares Out 9 M / FDA DECISION ON FEB.20 for Non-Opioid Pain Drug / UNKNOWN Gem = 500%+ Upside
Baudax Bio,(BXRX) a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal date of February 20, 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain.
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
ICCC =LOW FLOAT CORONAVIRUS PLAY about to explode brutally
The Company develops, manufactures and markets the First Defense® product line that provides “immediate immunity” against aggressive pathogens, including E. coli, coronavirus, and rotavirus
Market Cap: $38 M
Cash: $10 M
Price: $5.30
Share Out: 7.2 M
Top Shareholders:
Pessin (Norman H)...703.6K
Wellington ...683.3K
Rothschild...510.2K
Pessin (Sandra F)...270.0K
Brigham (Michael F)...204.8K
Heartland...175.0K
Crabb (Joseph H)...141.8K
Perritt Capital...120.0K
Pessin (Brian L)...110.0K
Antara Capital LP...105.0K
ICCC =LOW FLOAT CORONAVIRUS PLAY about to explode brutally
The Company develops, manufactures and markets the First Defense® product line that provides “immediate immunity” against aggressive pathogens, including E. coli, coronavirus, and rotavirus
Market Cap: $38 M
Cash: $10 M
Price: $5.30
Share Out: 7.2 M
Top Shareholders:
Pessin (Norman H)...703.6K
Wellington ...683.3K
Rothschild...510.2K
Pessin (Sandra F)...270.0K
Brigham (Michael F)...204.8K
Heartland...175.0K
Crabb (Joseph H)...141.8K
Perritt Capital...120.0K
Pessin (Brian L)...110.0K
Antara Capital LP...105.0K
ICCC =CORONAVIRUS
IGXT =MC $33M--FDA DECISION & LAUNCH OF CANNABIS Products partnered with Tilray bot milestones expected during THIS Quarter
IGXT =Price 0.36 -MC $33 M--FDA DECISION for Migraine drug on March 26 and Launch of Cannabis Products by partner Tilray expected during this Quarter !!!! Stock could run to $2 ahead of the FDA decision in March .GL
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
IGXT =MC $33M--FDA DECISION & LAUNCH OF CANNABIS Products partnered with Tilray bot milestones expected during THIS Quarter
IGXT =Price 0.36 -MC $33 M--FDA DECISION for Migraine drug on March 26 and Launch of Cannabis Products by partner Tilray expected during this Quarter !!!! Stock could run to $2 ahead of the FDA decision in March .GL
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
IGXT =Price 0.35 -MC $34 M--FDA DECISION for Migraine drug on March 26 & Launch of Cannabis Products expected during this Quarter !!!! Stock could run to $1++ ahead of the FDA decision in March .GL
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
IGXT =MC $34 M--FDA DECISION for Migraine Drug & Launch of Cannabis Products both expected during this Quarter !!!! Stock could run to $1 ahead of the FDA decision .GL
Intelgenx (IGXT)
Market Cap $34 M
Price 0.36
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
IGXT =MC $34 M--FDA DECISION for Migraine Drug & Launch of Cannabis Products both expected during this Quarter !!!!
Intelgenx (IGXT)
Market Cap $34 M
Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020
IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
UPPPPPPPPPP she goes again
BXRX =Mcap $82 M- FDA DECISION ON FEB.20 --Could run to $20 and more ahead of the potential FDA approval
BXRX =MC $82 M -Cash $20 M- Shares Out 9 M / FDA DECISION ON FEB.20 for Non-Opioid Pain Drug / UNKNOWN Gem = 500%+ Upside
Baudax Bio,(BXRX) a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal date of February 20, 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain.
BXRX =MC $82 M FDA DECISION ON FEB.20 --Could run to $20 and more in the coming days
BXRX =MC $82 M -Cash $20 M- Shares Out 9 M / FDA DECISION ON FEB.20 for Non-Opioid Pain Drug / UNKNOWN Gem = 500%+ Upside
Baudax Bio,(BXRX) a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal date of February 20, 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain.
BXRX =MC $79 M -Cash $20 M- Shares Out 9 M / FDA DECISION ON FEB.20 for Non-Opioid Pain Drug / UNKNOWN Gem = 500%+ Upside
Baudax Bio,(BXRX) a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal date of February 20, 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain.
STRONG BUY while its terrible underpriced
3 Weeks till FDA Decision ,,load up while its still terrible underpriced
BXRX =MC $79 M-FDA Decision NEXT month for Non-Opioid Pain Drug -Cash $20 M - O/S 9 M /--UNKNOWN Gem = 500%+ Upside
https://www.sec.gov/Archives/edgar/data/1780097/000119312519306813/g841356ex99_1s7g1.jpg
Baudax Bio,(BXRX) a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal date of February 20, 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain.
BXRX =MC $79 M--FDA Decision NEXT month for Non-Opioid Pain Drug-Cash $20 M - O/S 9 M / --UNKNOWN Gem = 500%+ Upside
https://www.sec.gov/Archives/edgar/data/1780097/000119312519306813/g841356ex99_1s7g1.jpg
Baudax Bio,(BXRX) a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal date of February 20, 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain.
strong buy
BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM
AHPI =EXPLODINGGGG BRUTAL CHEAP CORONAVIRUS
Market Cap $7 M -- Shares Out 4 M half of that owned by Insiders --Revenue $32 M = Undiscovered and HOT Coronavirus Gem ..$10-12 Stock here
"The new mass casualty ventilation line from Allied Healthcare Products has been designed from inception to meet the unique ventilation demands that can occur during a mass casualty event or pandemic. All of our mass casualty products are lightweight, robust, and easy to operate. Designed for surge capacity, these products are capable of providing reliable ventilation even in unpredictable environments and conditions. Whether used regularly or for stockpiling, these products require minimal periodic maintenance, reducing costs and ensuring these products are as simple to own as they are to operate. "
AHPI =EXPLODINGGGG BRUTAL CHEAP CORONAVIRUS
Market Cap $7 M -- Shares Out 4 M half of that owned by Insiders --Revenue $32 M = Undiscovered and HOT Coronavirus Gem ..$10-12 Stock here
"The new mass casualty ventilation line from Allied Healthcare Products has been designed from inception to meet the unique ventilation demands that can occur during a mass casualty event or pandemic. All of our mass casualty products are lightweight, robust, and easy to operate. Designed for surge capacity, these products are capable of providing reliable ventilation even in unpredictable environments and conditions. Whether used regularly or for stockpiling, these products require minimal periodic maintenance, reducing costs and ensuring these products are as simple to own as they are to operate. "
load up guys while its still brutally underpriced
BXRX=MC $79 M--FDA DECISION ON FEB.20
BXRX =MC $79 M -Cash $20 M - O/S 9 M / FDA Decision NEXT month for Non-Opioid Pain Drug --UNKNOWN Gem = 500%+ Upside
https://www.sec.gov/Archives/edgar/data/1780097/000119312519306813/g841356ex99_1s7g1.jpg
Baudax Bio,(BXRX) a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal date of February 20, 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain.
Market Cap only $3 Million --important results coming early next Quarter --Eye drops with MASSIVE market potential --BRUTALLY undpriced and unknown gem = Could run to $5
Topline data should be available next quarter.
https://seekingalpha.com/news/3533078-wize-pharma-completes-enrollment-in-post-marketing-study-of-eyecon-eye-drop
WIZP =Market Cap $3 Million --BIG Drug with clinical results in Q2 ..only 15.8 million outstanding shares trading at .20 .. Could hit $2-3 on positive results ..completely unknown gem
Topline data should be available next quarter.
https://seekingalpha.com/news/3533078-wize-pharma-completes-enrollment-in-post-marketing-study-of-eyecon-eye-drop
BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM
Still great entry at this low price
BXRX =MC $65 M--FDA DECISION next month ..GREAT News out today
BXRX =MC $65 M -Cash $20 M - O/S 9 M / FDA Decision NEXT month for Non-Opioid Pain Drug --Undiscovered low float stockwith brutal upside potential could hit $15 even before FDA Decision
Baudax Bio Announces PDUFA Date for Intravenous Meloxicam
https://finance.yahoo.com/news/baudax-bio-announces-pdufa-date-120010357.html
PDUFA Goal Date Set for February 20, 2020
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong. She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
BXRX =MC $65 M--FDA DECISION next month ..GREAT News out today
BXRX =MC $65 M -Cash $20 M - O/S 9 M / FDA Decision NEXT month for Non-Opioid Pain Drug --Undiscovered low float stockwith brutal upside potential could hit $15 even before FDA Decision
Baudax Bio Announces PDUFA Date for Intravenous Meloxicam
https://finance.yahoo.com/news/baudax-bio-announces-pdufa-date-120010357.html
PDUFA Goal Date Set for February 20, 2020
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong. She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
BXRX =MC $65 M--FDA DECISION next month ..GREAT News out today
BXRX =MC $65 M -Cash $20 M - O/S 9 M / FDA Decision NEXT month for Non-Opioid Pain Drug --Undiscovered low float stockwith brutal upside potential could hit $15 even before FDA Decision
Baudax Bio Announces PDUFA Date for Intravenous Meloxicam
https://finance.yahoo.com/news/baudax-bio-announces-pdufa-date-120010357.html
PDUFA Goal Date Set for February 20, 2020
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong. She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
FDA DECISION NEXT MONTH
(FDA) has set a PDUFA goal date of February 20, 2020
https://ih.advfn.com/stock-market/NASDAQ/baudax-bio-BXRX/stock-news/81576432/baudax-bio-announces-pdufa-date-for-intravenous-me
VXRT = CORONAVIRUS EXPLODINGGGG
VXRT = CORONAVIRUS EXPLODINGGGG
VXRT = HOT Coronavirus gem and the cheapest one ..could run to $2-4
Strong Insider Ownership
https://www.cnbc.com/quotes/?symbol=VXRT&qsearchterm=vxrt&tab=ownership
VXRT this coronavirus gem likely to explode tomorrow
Global Health Officials On High Alert As Virus's Rapid Spread Confounds Expectations
https://www.zerohedge.com/markets/stocks-slide-cnn-report-suggesting-coronavirus-has-reached-us
VXRT =HOT coronovirus gem indeed
WIZP..MC $2 M -HOT LOW FLOAT GEM
WIZP =Market Cap $2 M --Potential Blockbuster with Results in Q2 / COMPLETELY unknown gem ...MASSIVE upside potential here
Topline data should be available next quarter.
https://seekingalpha.com/news/3533078-wize-pharma-completes-enrollment-in-post-marketing-study-of-eyecon-eye-drop
Baudax Bio Inc. (BXRX) PT Raised to $12 at Oppenheimer
https://www.streetinsider.com/Analyst+Comments/Baudax+Bio+Inc.+%28BXRX%29+PT+Raised+to+%2412+at+Oppenheimer/16351861.html
$100 or more likely with only 100K shares on the float .GL